# Nectin-4 expression

Source: https://onco.cc/biomarkers/nectin-4-expression/  
OnCo record `nectin-4-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nectin-4 is expressed by almost every urothelial cancer, so enfortumab vedotin is given without a test. Nectin-4 amplification is being studied as a marker of especially strong response.

## Summary

Enfortumab vedotin (Padcev) is labelled alone and with pembrolizumab for locally advanced or metastatic urothelial cancer with no Nectin-4 requirement; the pivotal EV-201 and EV-301 trials enrolled without testing after screening showed near-universal expression. Retrospective work links NECTIN4 amplification to higher response rates; a Nectin-4 PET tracer is in early trials. No approval or guideline sets a threshold.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: Nectin-4; NECTIN4 expression; Nectin-4 positive; Nectin-4 H-score
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- PADCEV prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed

## Connected records

- biomarkers: [FGFR3 alteration (mutation or fusion)](https://onco.cc/biomarkers/fgfr3-alteration/), [TROP2 expression](https://onco.cc/biomarkers/trop2-expression/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/)
- terms: [Gene amplification and copy-number change](https://onco.cc/terms/gene-amplification/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/)

---
JSON: https://onco.cc/api/v1/entities/nectin-4-expression.json